Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Very high HDL-C may not reduce CV risk or protect against high LDL-C

10 Jan 2018

Although higher levels of HDL-cholesterol (HDL-C) are associated with reduced cardiovascular disease (CVD) risk, the relationship is not linear and after an intermediate range of 50–70 mg/dL, very high HDL-C is not always associated with lower CV risk. [Pagidipati P, AHA 2017, abstract 779]

In a study of data from 22,569 adults without prior CVD followed for a median of 19.5 years, 6,539 died, 31 percent of which were CV deaths. Comparing to a reference point of 50 mg/dL and adjusting for factors including age, race and systolic blood pressure, lower HDL-C was associated with higher CVD composite events (CV death, MI, angina or stroke), but higher HDL-C was not, suggesting a U-shaped relationship between HDL-C and CV risk.

“Higher HDL-C is not always better,” said lead researcher Dr Neha Pagidipati of the Duke Clinical Research Institute in Durham, North Carolina, US. “This may help us understand why many cholesteryl ester transfer protein [CETP] inhibitor trials and niacin trials didn’t necessarily result in lower CVD with higher HDL-C.”

“The benefit of high HDL-C was also not fully balanced by the risk of high LDL-C, especially in women,” Pagidipati added. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.